Inspira Technologies
- Company typePublic
- Founded2018
- HeadquartersRa'anana, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Inspira Technologies firmographics
Firmographics- Name
- Inspira Technologies
- Legal name
- Inspira-Technologies OXY B.H.N. LTD.
- Website
- https://inspira-technologies.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Inspira Technologies industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing (333413)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC)
- akta.pro secondary industries
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG), Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG)
Keywords
Where Inspira Technologies is headquartered
LocationHeadquarters
- HQ city
- Ra'anana
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
Inspira Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Revenue model
- Capital Equipment Sales: One-time sale of INSPIRA ART100 and ART500 extracorporeal oxygenation systems to hospitals and medical centers, supplemented by installation, training, and warranty.
- Recurring Consumables and Disposables: Recurring revenue from cartridges, sensors, and single-use disposables used per patient treatment, driving a razor/blade model attached to installed ART100/ART500 bases.
- AME Platform and Devices: Sales of additively manufactured electronics (AME) platforms and printed electronic devices for medical, defense, and quantum sensing applications, with associated consumables.
- Quantum-Enabled AI Services: Emerging revenue stream from quantum computing access, AI-driven blood analytics, and data services powered by the Qarakal Quantum partnership.
- Strategic Equity Placements: Capital raised through registered direct offerings and private placements with H.C. Wainwright and Alliance Global Partners acting as placement agents.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Quote-based capital purchase plus recurring consumables |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels6 records
Inspira Technologies product offering
Product offeringCore offering
Inspira Technologies develops and sells extracorporeal blood oxygenation systems for acute respiratory support, headlined by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) and the next-generation INSPIRA ART500 built around proprietary VORTX Orbital Blood Oxygenation. The systems are paired with HYLA AI-powered continuous blood sensors, plug-and-play disposable cartridges, and a convertible dual-lumen cannula, generating both capital equipment sales and recurring consumable revenue from hospital ICUs and academic medical centers.
Product overview
Inspira Technologies operates a platform-plus-modules medical-device portfolio for acute respiratory support and extracorporeal blood oxygenation, anchored by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) core system with its integrated HYLA 1 Blood Sensor, and the next-generation INSPIRA ART500 (Gen 2) built around the proprietary VORTX Orbital Blood Oxygenation technology and HYLA 2 continuous blood sensor. The HYLA sensors function as AI-powered monitoring modules that feed decision-making data into an algorithm-enhanced control unit with process automation (auto-priming and hemoprotective flow regulation). Building on this core, the company has introduced development-stage offerings such as the INSPIRA Cardi-ART device for cardiac-arrest oxygenation, signed a term sheet for an AI-powered liquid biopsy diagnostics platform, and — following the acquisition of Nano Dimension's Additively Manufactured Electronics (AME) platform and rebrand to QTREX Quantum — added a parallel QTREX AME platform business targeting quantum computing connectivity, with deployments to U.S. defense, top-10 U.S. enterprise, and academic customers. The Bites AI platform is embedded across the medical systems as an AI layer for training, operational efficiency, and customer support.
Differentiator
Problem solved
Functional benefit
Brands
- INSPIRA ART100: Gen 1 FDA 510(k) cleared (K232788) extracorporeal blood oxygenation system for Cardio-Pulmonary Bypass, integrating the HYLA 1 Blood Sensor.
- INSPIRA ART500
- HYLA
- VORTX
- QTREX AME Platform
- ALICE
- INSPIRA Cardi-ART
Products and services
- INSPIRA ART100
Quantifiable outcome
- $49.5 million in binding purchase orders across ART and AME products
- +3 more outcomes
Companies that use Inspira Technologies
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles3 records
Inspira Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability8 records
Feature8 records
Inspira Technologies partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship, core and supporting.
- Nano DimensionflagshipAcquired Nano Dimension's Additively Manufactured Electronics (AME) platform and associated assets, including a portfolio of printed-electronics patents and $200M+ of cumulative development investment. Inspira is integrating AME capabilities across its medical and quantum sensor roadmap.
- Qarakal QuantumflagshipJoint development partnership to connect Inspira's HYLA blood sensor platform with Qarakal's quantum computing infrastructure, enabling advanced AI analytics on blood data. Underpins Inspira's quantum-computing pivot and exposure to the $72B projected quantum market by 2035.
- Glo-Med NetworkscoreU.S. distribution and clinical sales partner for Inspira's ART platform, providing field coverage of American hospital systems and supporting purchase orders such as the NYU Langone Health deployment.
- Bites Learning Ltd.coreStrategic alliance focused on AI, supporting the development of HYLA blood sensor analytics and Inspira's broader artificial intelligence roadmap.
- Terumo CardiovascularcoreOEM agreement with Terumo Cardiovascular to integrate Inspira's extracorporeal oxygenation technology with Terumo's cardiovascular portfolio, expanding access to global hospital customers.
- CIO MED GROUPcoreCentral American distribution partner supporting Inspira's regional sales of ART and AME products across hospital customers.
- Waas GroupcoreEuropean distribution partner extending Inspira's reach across EU hospital systems for extracorporeal oxygenation and AME offerings.
- InnovimedsupportingClinical trials partner supporting execution of Inspira's clinical studies for the ART100/ART500 extracorporeal platform.
- Zriha MedicalcoreProduction partner providing manufacturing capacity and supply chain expertise for Inspira's medical device production line.
- EnnocuresupportingCollaboration partner developing bio-electronic treatment technologies complementary to Inspira's extracorporeal platform.
- Sheba Medical CentercoreClinical collaboration partner and customer site supporting Inspira's technology development, clinical studies, and adoption within a leading Israeli academic medical center.
- Westchester Medical CentersupportingClinical partner and customer site where the first patient was treated with Inspira's extracorporeal oxygenation technology.
- Perfusion Solution Inc.supportingCollaboration partner supporting perfusion-related clinical and commercial activities for Inspira's extracorporeal platform.
- Ben-Gurion UniversitysupportingAcademic research partner supporting R&D and clinical studies tied to Inspira's blood sensing and oxygenation programs.
- GlobalLogicsupportingTechnology partner providing software engineering and product development support for Inspira's digital and AI platforms.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
Inspira Technologies competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Global medtech incumbent with a broad cardiac and respiratory support portfolio (including ECMO and perfusion systems). Comparable as the established scale player Inspira is targeting in the extracorporeal blood oxygenation market, but Medtronic operates across many other device categories rather than specializing in awake extracorporeal oxygenation.
- Abbott (CentriMag): Broader medtech incumbent with a CentriMag and ECMO/perfusion presence. Comparable as a major cardiac support supplier addressing overlapping ICU and surgical customers, though Abbott's portfolio extends well beyond extracorporeal oxygenation.
- Abiomed (Johnson & Johnson): J&J-owned circulatory and respiratory support specialist (Impella, plus legacy ECMO programs). Comparable as a higher-resource medtech player building next-generation support technologies in adjacent cardiac and respiratory care segments that Inspira targets.
Direct peers
- Getinge (Maquet): Direct competitor in extracorporeal life support and perfusion through its Maquet/Cardiohelp ECMO and heart-lung machine lines. Comparable as a leading hospital supplier of oxygenation and cardiopulmonary support equipment, competing for the same ICU and cardiac surgery customer segment as the INSPIRA ART100/ART500.
- LivaNova: Direct peer in cardiopulmonary bypass and extracorporeal circulation through its heart-lung machine and oxygenator portfolio. Comparable in addressing the same cardiac surgery and perfusion market that Inspira's ART100/ART500 targets, with overlapping hospital customers and regulatory pathways.
- Terumo Cardiovascular: Existing OEM partner of Inspira and direct peer in oxygenators, perfusion circuits, and cardiovascular surgical devices. Comparable as both a commercial channel for Inspira's technology and a competing supplier of integrated cardiovascular solutions to the same global hospital customer base.
- Xenios (Fresenius Medical Care): Specialist in extracorporeal lung and heart assist therapies (iLA, ECCO2R) acquired by Fresenius. Comparable as a focused player in minimally invasive and extracorporeal respiratory/circulatory support, directly competing with Inspira's positioning in awake and non-invasive oxygenation.
- Nipro Medical: Manufacturer of dialysis, oxygenator, and ECMO disposables. Comparable as a supplier of oxygenation and perfusion consumables to hospitals, with overlapping product economics (capital + consumables) similar to Inspira's razor/blade model.
Emerging players
- ALung Technologies: Early-commercial-stage company developing extracorporeal CO2 removal and lung support systems (Hemolung). Comparable as a focused emerging competitor in extracorporeal respiratory support, with similar technology profile and clinical use cases to Inspira's VORTX/ART platform.
Others
- Nano Dimension: Seller of the AME platform Inspira acquired in April 2026, and a 3D-printed electronics specialist. Comparable as the originator of the AME business Inspira is now operating, providing a public-market reference point for the AME/quantum connectivity vertical Inspira is pivoting into.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Inspira Technologies social profiles
Digital presenceInspira Technologies compliance and trust
Trust signalCompliance3 records
Inspira Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inspira Technologies leadership team
Management profileNumber of profiles
Profiles14 records
Inspira Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
Inspira Technologies funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inspira Technologies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inspira Technologies
What does Inspira Technologies do?
Inspira Technologies develops and sells extracorporeal blood oxygenation systems for acute respiratory support, headlined by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) and the next-generation INSPIRA ART500 built around proprietary VORTX Orbital Blood Oxygenation. The systems are paired with HYLA AI-powered continuous blood sensors, plug-and-play disposable cartridges, and a convertible dual-lumen cannula, generating both capital equipment sales and recurring consumable revenue from hospital ICUs and academic medical centers.
Is Inspira Technologies a public or private company?
Inspira Technologies is a public company. It is classified as public and is currently operating.
When was Inspira Technologies founded?
Inspira Technologies was founded in 2018. It employs 11 to 50 people.
Where is Inspira Technologies based?
Inspira Technologies is headquartered in Ra'anana, Israel, in the Middle East region.
How does Inspira Technologies make money?
Five revenue lines are on record. Capital Equipment Sales are the primary driver. The others are recurring Consumables and Disposables, AME Platform and Devices, quantum-Enabled AI Services and strategic Equity Placements.
Who are Inspira Technologies's main competitors?
Broad incumbents on record are Medtronic, Abbott (CentriMag) and Abiomed (Johnson & Johnson). Direct peers are Getinge (Maquet), LivaNova, Terumo Cardiovascular, Xenios (Fresenius Medical Care) and Nipro Medical. ALung Technologies is listed as an emerging player. Nano Dimension is listed as an others.
Does Inspira Technologies have an API?
No public API is recorded for Inspira Technologies.
What industry is Inspira Technologies in?
Inspira Technologies's product category is Medical Devices. Its primary akta.pro industry code is HLAHAGAC, Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home), with a secondary code of HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 339112 and its SIC code is 3845.